Bacillus Calmette-Guérin
Bacillus Calmette-Guérin
Overview
Bacillus Calmette-Guérin (BCG) is a live attenuated strain of Mycobacterium bovis, originally developed by Albert Calmette and Camille Guérin through serial passage of a virulent bovine tuberculosis isolate between 1908 and 1921. It remains the only licensed vaccine for the prevention of tuberculosis (TB) globally and is among the most widely administered vaccines in human history, particularly in TB-endemic regions. BCG's mechanism of action involves the induction of trained innate immunity and adaptive cellular immune responses, engaging dendritic cells, natural killer (NK) cells, and T lymphocytes, and promoting the release of proinflammatory cytokines including IFNG (interferon-gamma). These immunostimulatory properties underpin not only its prophylactic role against mycobacterial disease but also its established use as an immunotherapeutic agent in oncology.
In the oncological setting, BCG is administered as an intravesical instillation—directly into the bladder—following transurethral resection, and constitutes the standard-of-care adjuvant treatment for high-risk non-muscle-invasive bladder cancer (HR-NMIBC). Its antitumor effect is mediated through local activation of the tumor microenvironment, triggering immune-mediated destruction of residual cancer cells. Despite its clinical utility, BCG has notable limitations: its protective efficacy against pulmonary tuberculosis in adults is variable and often insufficient, its use in livestock is constrained by cross-reactivity with tuberculin diagnostic tests, and a subset of bladder cancer patients exhibit disease that is unresponsive to BCG therapy—a clinically significant challenge driving substantial contemporary research into alternative and combinatorial treatment strategies.
Focus of Latest Publications
Recent literature reflects two principal and intersecting research trajectories for BCG: its continued centrality as the standard of care in bladder cancer management, and ongoing efforts to improve or supplant its role in TB prophylaxis.
bladder cancer: Standard of Care and Emerging Alternatives
BCG intravesical immunotherapy remains the established adjuvant treatment for HR-NMIBC, as confirmed across multiple recent studies. A 2026 study in In Vivo examined the impact of older patient age on outcomes of intravesical BCG therapy, positioning it firmly within standard clinical protocols. Similarly, research published in Scandinavian Journal of Urology investigated whether asymptomatic bacteriuria (ABU) prior to BCG immunotherapy influences oncological outcomes and treatment tolerability in NMIBC patients—a pragmatic clinical question with direct implications for patient selection and pre-treatment optimization.
A significant area of recent investigation concerns patients whose disease becomes BCG-unresponsive, a condition defined by persistent or recurrent high-risk disease despite adequate BCG exposure. A 2026 budget impact analysis published in the Journal of Medical Economics modeled the economic consequences of adopting nadofaragene firadenovec—a gene therapy—for adults with BCG-unresponsive NMIBC presenting with carcinoma in situ (CIS±Ta/T1), from a US third-party payer perspective. This study reflects a broader clinical shift toward novel salvage therapies for patients who fail BCG. Concurrent work published in the European Journal of Cancer critically examined censoring patterns and inconsistent results in clinical trials evaluating checkpoint inhibitors and adjuvant BCG for HR-NMIBC, highlighting methodological concerns that complicate the interpretation of comparative efficacy data across this emerging therapeutic landscape. Agents including atezolizumab, durvalumab, and sasanlimab represent the immune checkpoint inhibition approaches being evaluated in this context, as the tumor microenvironment of NMIBC is increasingly understood through markers such as TP53 mutational status and immune cell infiltration patterns.
Molecular stratification of NMIBC patients is also advancing BCG research. A 2026 study in Functional & Integrative Genomics constructed an integrated molecular classification system that identified distinct prognostic clusters; IMC1 and IMC3 clusters demonstrated improved progression-free survival following BCG instillation in patients treated per European Association of Urology (EAU) guidelines, suggesting that molecular subtyping may refine patient selection for BCG therapy.
BCG's role has also been explored in the context of upper tract urothelial carcinoma (UTUC). Research published in the World Journal of Urology described patterns of adjuvant intracavitary instillation—with either chemotherapy or BCG—following endoscopic management of UTUC and evaluated associated recurrence risk, extending BCG's therapeutic application beyond the bladder.
A novel engineering approach published in ACS Nano demonstrated the synthesis of core-shell Au@ZnxMn1-xS nanoparticles (AZMS) covalently conjugated to BCG to generate an engineered bacterium (AZMB), subsequently encapsulated in a hyaluronic acid matrix to fabricate a functional implant. This construct was investigated for synergistic immunotherapy of triple-negative breast cancer, with zinc ions playing a role in the nanoparticle composition. In a related vein, research in the Journal of Controlled Release described squid tentacle-mimetic magnetically targeted nanomotors designed to overcome the bladder mucosal barrier and enhance the delivery of therapeutics, contextualizing BCG as the current clinical benchmark that next-generation intravesical delivery systems aim to improve upon.
A rare but serious complication of BCG vaccination—disseminated BCG infection—was reported in the Pediatric Blood & Cancer journal in the context of an infant receiving treatment for acute lymphoblastic leukemia, underscoring immunosuppression as a contraindication and a clinically important safety concern for BCG administration in vulnerable populations.
Tuberculosis Vaccination: Limitations and Next-Generation Approaches
BCG's well-documented limitation in providing consistent protection against adult pulmonary TB continues to motivate vaccine research. A 2026 study in Archives of Microbiology developed a tuberculosis subunit vaccine based on a fusion protein (AP2) incorporating antigens including the ArsR family transcriptional regulator Rv2642 and the pyridoxamine 5'-phosphate oxidase Rv2074, formulated with a novel adjuvant (ASM), explicitly positioning this approach as an improvement over BCG's incomplete adult efficacy. Separately, research published in Vaccine described recombinant Mycobacterium smegmatis engineered to produce a functional M. tuberculosis ESX-1 secretion system, demonstrating protection in a murine model of bovine TB without sensitizing animals to tuberculin—thereby addressing BCG's key limitation in livestock use, where tuberculin-based diagnostic interference prevents widespread veterinary vaccination programs.
At the global public health level, a large ecological analysis published in PLOS One examined routine childhood immunization data from 2010 to 2023 using WHO/UNICEF datasets, including BCG coverage alongside DTP3, HepB3, Hib3, MCV2, and Pol3, to assess whether vaccination reduces child mortality despite structural inequality—contextualizing BCG within the broader landscape of essential childhood immunization programs.